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Abstract The efficacy of therapeutic modalities in chronic
myeloid leukemia (CML) depends on both genetic and
epigenetic mechanisms. This review focuses on epigenetic
mechanisms involved in the pathogenesis of CML and in
resistance of tumor cells to tyrosine kinase inhibitors leading
to the leukemic clone escape and propagation. Regulatory
events at the levels of gene regulation by transcription
factors and microRNAs are discussed in the context of
CML pathogenesis and therapeutic modalities.
Keywords CML . Epigenetics . microRNA . Tyrosine
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Introduction
It has been over half a century since a specific chromosomal
aberration – the Philadelphia chromosome (Ph chromo-
some), was found in chronic myeloid leukemia (CML) [1],
but still many questions regarding molecular mechanisms of
pathogenesis in CML remain unanswered. The CML genet-
ics provided detailed analyses of the Ph chromosome that is
a result of a reciprocal translocation t(9;22)(q34;q11) ac-
companied by breaks on long arms of chromosome 9
(9q34) proximally from the ABL gene and on long arms of
chromosome 22(q11) with BCR (Breakpoint Cluster
Region) [2]. The hybrid gene BCR-ABL product translates
a chimeric protein with strong and constitutive tyrosine
kinase activity that phosphorylates target proteins to facili-
tate expansion of hematopoietic stem and progenitor cells.
The end of the last century was marked by significant
progress in CML treatment following the introduction of
the tyrosine kinase inhibitor (TKI) imatinib (IM) that binds
to the kinase domain (KD) of BCR-ABL and inhibits its
tyrosine kinase activity [3]. Despite the high efficiency of
imatinib therapy, still approximately 30 % of patients devel-
op resistance to imatinib resulting in first line therapy fail-
ure. Imatinib resistance due to the mutations in KD of BCR-
ABL can be bypassed by 2nd line TKIs such as dasatinib or
nilotinib [4]. Resistance to the 2nd line therapy also devel-
ops and not surprisingly is also associated with specific KD
mutations [5]. Genetic mechanisms at the level of KD
sequence integrity must be important; but other mechanisms
of primary or acquired resistance to TKI are also now being
studied including additional clonal aberrations, BCR-ABL
overexpression, and TKI bioavailability. However, apart
from BCR-ABL, there are other genetic or epigenetic alter-
ations that are still unknown as they may contribute to CML
stem cells survival during a long term TKI therapy that
successfully inhibits the BCR-ABL activity but is not
curative. One can imagine that TKI therapy may in the
future benefit from being combined with other agents
in order to achieve deep and long term molecular
responses.
Abnormal epigenetic regulation of the expression of
CML-associated genes may play a critical role in its patho-
genesis and in the mechanisms modulating therapeutic re-
sponsiveness. Epigenetics is thought to involve well
recognized regulatory mechanisms of gene expression such
as DNA methylation or covalent post-translational modifi-
cations of histone core proteins that lead to changes in the
chromatin accessibility for mRNA transcription regulation
[6, 7]. As well as nuclear events, other mechanisms includ-
ing non-coding RNA-mediated (by microRNAs, miRs) spe-
cific mRNA silencing at the levels of translation and RNA
stability are also considered to be very powerful epigenetic
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mediators to modulate CML expression profiles and pheno-
typic outcomes. MicroRNAs are able to control hundreds of
mRNAs and thus they control broad physiological and
pathological features including tumor aggressiveness.
Unlike mRNAs, microRNAs are stable and therefore can
be routinely quantitated and potentially may also serve as
disease biomarkers.
This review summarizes the role of epigenetics in CML,
and focuses on DNA methylation and histone modification
as well as post-transcriptional effects of microRNAs in the
pathogenesis of CML from diagnosis and throughout
treatment.
DNA Methylation in CML
The methylation of CpG islands is an active enzymatic and
transcription-inhibiting control mechanism that balances the
levels of gene expression that is frequently dysregulated in
hematological malignancies. A large number of genes
(mostly tumor suppressors) are inactivated by hypermethy-
lation of CpG islands mainly in the promoter regions while
some genes (such as oncogenes) are hypomethylated. This
phenomenon has been documented to play a critical role in
both solid tumors and leukemias [8].
ABL1 (v-abl Abelson murine leukemia viral oncogene
homolog 1) methylation at its Pa promoter represents a
likely marker of CML pathogenesis [9, 10]. The frequency
of methylation in chronic phase (CP) CML however ranges
from 26 % [11] to 77 % [12], 78 % [10] and 81 % [13•]. Sun
et al. [14] confirmed the high incidence of Pa methylation in
CP bone marrow (BM) samples in contrast to normal BM.
They observed copies of ABL1 promoter Pa to be methylat-
ed 20–60 % in BM from 7 CP CML patients at diagnosis.
No Pa methylation was detected in normal BMs or colonies
derived from them. On the other hand, most colonies from
CP CML patients were methylated at the Pa. The authors
suggested that ABL1 Pa methylation was an early marker of
CML in BM. Asimakopoulos et al. [9] demonstrated that in
accelerated phase (AP) CML, methylation is likely to be an
allele-specific process, since each progenitor cell carries
both methylated and unmethylated alleles. This paragraph
documents the promising but also quite highly disputed
significance of the ABL1 hypermethylation in CML.
One of the most frequently studied genes in leukemias is
the cell cycle regulating gene p15 (CDKN2B). Cyclin-
dependent kinase (CDK) inhibitor p15 (p15Ink4b) together
with CDK4 or CDK6 are known to negatively regulate
cyclin D transcription leading to inhibition of cell cycle
progression. Abnormal hypermethylation of p15 gene
regions has been associated with the disease progression in
myelodysplastic syndrome (MDS) [15, 16] and with the
poor outcome in acute myelogenous leukemia (AML)
[17]. The clinical importance of p15 methylation in AML
patients is not conclusive [18, 19]. Similarly, the signifi-
cance of p15 methylation in CML patients is not fully
understood as the p15 promoter in CML patients is hypo-
methylated [20, 21], while others observed p15 hyperme-
thylation in 18 % and 24 % of patient samples, respectively
[12, 22]. To conclude, p15 methylation in CML patients
requires additional work to fully understand its clinical
relevance.
Ras association domain-containing protein 1 (RASSF1A)
is another candidate gene for DNA methylation. Avramouli
et al. [23] however did not observe in 41 CML patients in
different stages of the disease any methylation of RASSF1A
that is normally involved in cell cycle control. In contrast,
RASSF1A was methylated in the CML-derived K562 cell
line. Methylation of RASSF1A is not likely to be critical step
in the pathogenesis and/or the progression of primary CML
samples, although it seems to have clinical importance in
Hodgkin disease [24] and in epithelial cancers [25].
Methylation of additional genes was later associated with
progression of CML and potential resistance to TKI treat-
ment. For instance, two genes involved in development,
TFAP2A (transcription factor AP-2 alpha) and EBF2 (early
B-cell factor 2), were found to be more methylated in blast
crisis (BC) compared to CP in the study of 55 CP CML and
8 BC CML samples [25]. The autophagy related 16-like 2
gene ATG16L2 was methylated in 69 % of CML patients.
Patients with methylated ATG16L2 had a lower probability
of achieving a major molecular response (MMR) at 12 or
18 months compared with the unmethylated cases at base-
line [25].
One of the candidate tumor suppressor genes, often meth-
ylated in many malignancies, is the death-associated protein
kinase 1 DAPk1. The DAPk subfamily is part of the Ser/Thr
kinase family, whose members show significant homology
in their catalytic domains and have cell death-associated
functions such as the capability of inducing apoptosis.
Qian et al. [26] examined the methylation pattern of
DAPk1 in 49 CML patients at different stages of the disease
(29 patients in CP, 3 in AP and 17 in BC). Aberrant meth-
ylation of DAPk1 was observed in 51 % of CML cases. A
correlation between gender and methylation status of
DAPk1 and also with the CML stages was found. These
results indicate that DAPk1 methylation may play a signif-
icant role in the CML progression.
Recently, a significant methylation in CML progressed to
AP or BC was found near five genes that were selected
based on genome wide methylation studies in K562 cells,
OSCP1 and TFAP2E, or were detected to be hypermethy-
lated in patients with myeloproliferative neoplasms, PGRA
and PGRB; CDKN2B (p15) was found to be deleted in
K562 [13]. Moreover, a significant increase in the number
of methylated genes in advanced stages of the disease was
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also noted. On the other hand, no significant differences in
overall survival between patients in CP with 0–4 hyper-
methylated genes compared to CP with 4–10 hypermethy-
lated genes were observed.
The methylation status of additional genes observed in
several studies with CML patients in different stages of
disease is summarized in Table 1.
DNA Methylation Inhibitors (DNMTi) in CML
Nowadays, several drugs, especially demethylating agents,
targeting DNA methyl transferase 1, are being utilized in
AML and MDS [32] and are strongly considered also in
CML. The most abundantly tested DNMTi are 5-azacitidine
and 5-aza-2´-deoxycitidine (decitabine). These agents are
incorporated into both DNA and RNA during replication or
transcription, respectively, and inhibit effects of DNA meth-
yltransferase (DNMT) [33]. Kantarijan et al. [34] reported
the results of decitabine treatment in 130 CML patients not
previously treated with imatinib. The patients were treated
with decitabine at 100 mg/m2 over 6 hours every 12 hours x
5 days (1000 mg/m2) in the first 13 patients, 75 mg/m2 in the
subsequent 33 patients, and 50 mg/m2 in the remaining 84
patients. Hematological response rates were 28 % in BC,
55 % in AP, and 63 % in CP. Severe and prolonged myelo-
suppression was one of the side effects during this therapy.
A median of three courses were required to achieve optimal
response suggesting that the decitabine effect on leukemia
cells is slow but continuous. A phase I study of low-dose
prolonged exposure to decitabine treatment in 50 patients
(44 with AML/MDS, 5 CML, and 1 acute lymphoblastic
leukemia (ALL)) with myeloid malignancies has shown that
most of the hematologic and/or cytogenetic responses were
achieved at a dose of 15 mg/m2 for 10 days [35, 36].
Decitabine was also used in a phase II trial in 25 CML
patients previously treated with imatinib that developed
resistance [21] at a dose of 15 mg/m2 intravenously daily,
5 days a week for 2 weeks in combination with imatinib
600 mg orally daily in 18 and 10 patients with CML in AP
and BC, respectively. The combination therapy was well
tolerated with mild toxicities limited to myelosuppression.
Similarly to the phase I trial, where decitabine was applied
alone, the overall hematologic response rate was 30 % in BC
and 50 % in AP. Moreover, the hematologic response rate
was higher in patients without any mutation in the BCR-
ABL kinase domain (KD) than in those with mutations.
Based on these findings, the authors suggested that decita-
bine cannot efficiently destroy tumor cell resistant to
imatinib.
Hydralazine and valproate are now being tested for
their potential to inhibit DNA methylation and histone
deacetylation, although they are commonly used as an anti-
hypertensive and epileptic drug, respectively. Additionally,
they have shown promising results in combination with
cytotoxic chemotherapy or alone in the treatment of several
solid and hematologic neoplasias, including MDS [37, 38].
Cervera et al. [39] evaluated the effect of these agents on the
response rates and their role in reverting the resistance to IM
in CML patients with acquired resistance who had no access
to 2nd generation TKI [39]. Eight patients received hydral-
azine 182 mg (fast acetylators) or 83 mg (slow acetylators)
daily, magnesium valproate 30 mg/kgt.i.d. and the same
dose of IM at the time of progression. Mild neurologic
toxicity was the only side effect during the treatment and
no toxicity of grade 3/4 was observed. All but one of the
patients achieved hematologic and cytogenetic responses or
at least stabilization of disease and the overall survival was
63 % at 18 months.
Therapy Modulating Histone Modifications in CML
Histone modifications are an integral part of gene regulation
involving transcription as well as other cellular processes
within the nucleus. Histone modifications involve acetyla-
tion, methylation, phosphorylation [40] and other posttrans-
lational modifications that mark sites of chromatin
accessibility, DNA integrity and repair, transcription and
replication [41]. Each of the core histones is strongly con-
served throughout evolution and can be modified at
arginine-(R) or lysine-(K) residues and also at other less
studied residues [42]. Histone methylation and acetylation
are the most investigated modifications that are reversible.
In general, malignant tissues demonstrate not only methyl-
ation of DNA, but also changes in histone modification
resulting in chromatin condensation rate with effects on
proliferation, differentiation and finally on tumor suppres-
sion. Pro- and anti-apoptotic genes and cell cycle genes are
also widely studied targets of histone modifications in
Table 1 DNA methylation status in CML patients
Gene Methylation status by CML stages %
CP AP BC
Calcitonin [27] 6 63 92
HIC1 [28] 50 – 100
ER [29] 50 – 100
PDLIM4 [13•] 13 29 33
HOXA4 [30] 60 – 91
HOXA5 [30] 33 – 87
DDIT3 [31] 68 100 53
CP Chronic phase; AP Accelerated phase; BC Blast crisis
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cancer cells [43, 44]. Specific enzymatic machinery is in-
volved in gene regulatory effects involving specific histone
acetylation including histone deacetylases (HDAC) and his-
tone acetyltransferases (HATs). In CML, histone modifica-
tions have been studied since HDAC inhibitors were
developed.
HDAC inhibitors, that may have the potential to restore
normal acetylation of histone proteins and transcription
factors, can be classified into several groups: aliphatic acids
(phenylbutyrate), cyclic peptides (romidepsin), benzamides
(entinostat), electrophilic ketones, and hydroxamates
(vorinostat) [33, 45]. At present, there also exist additional
compounds such as panobinostat. In addition, valproic acid
(VA), is also considered to have inhibition effects on
HDAC. The results of the therapy with VA in combination
with hydralazine are mentioned above.
Several HDAC inhibitors can target genes involved in the
growth arrest and apoptosis, including one of the most
studied inhibitors, suberoylanilide hydroxamic acid
(SAHA, vorinostat), which has been approved by FDA
for the treatment of cutaneous T-cell lymphoma [46].
Nimmanapalli et al. [47] observed that the treatment with
SAHA alone induced the expression of p21 and/or p27, but
decreased the mRNA and protein level of BCR-ABL in
K562 and LAMA-84 cells. Moreover, co-treatment with
SAHA and IM caused stronger down-regulation of the lev-
els compared to either drug alone. The BCR-ABL protein
level was also notably decreased in CD34+ cells derived
from BC CML patients treated with IM and the apoptosis
was induced. It is possible that the SAHA treatment enhan-
ces the cytotoxicity of IM and that it may show activity
against imatinib-refractory BC CML [47]. These results are
in accordance with the study of Fiskus et al. [48] evaluating
the effects of vorinostat and dasatinib (2nd generation TKI)
co-treatment, which caused attenuation of the BCR-ABL
protein level and induction of apoptosis in imatinib-
sensitive and imatinib-resistant cells as well as in primary
CML cells from patients in advanced stages of the disease.
This mechanism of how hydroxamates function on CML
cells remains unclear. It is suggested that hydroxamates
(LAQ824, LBH589, and vorinostat) may induce acetylation
and inhibition of non-histone protein Heat Shock Protein 90
(a chaperone for BCR-ABL), and thus promotes polyubi-
quitinylation and proteasomal degradation of BCR-ABL
[48, 49].
MicroRNAs in CML
As pointed out above, the posttranscriptional level is as
important as chromatin level in guidance of the epigenetic
regulations. MicroRNAs are evolutionarily conserved tiny
RNA molecules with potentially great regulatory functions
in many biological processes in humans, animals and plants.
Their regulatory functions are processed through the com-
plementarities of their “seed sequence“ and 3’UTR of the
targeted gene. If the complementarities are incomplete, the
translation into a protein is blocked. In the case of perfect
complementarities, the RNA-induced silencing complex
(RICS) induces mRNA degradation.
The number of known microRNAs continuously
increases. Up to now, more than 1000 pre-microRNAs have
been annotated in the human genome. Based on bioinfor-
matic predictions, it is expected that more than a half of gene
products in the human genome may be regulated by
microRNAs, with each microRNA capable of regulating
hundreds of genes [50].
When studying microRNAs associated with CML, sev-
eral important issues arose:
(i) what is the microRNA expression profile specificity in
CML pathogenesis ?, (ii) can some microRNAs be regulated
by BCR-ABL or do microRNAs target BCR-ABL ?, and
finally (iv) what are the microRNA targets in CML and are
they are involved in CML-associated processes ?
We and others demonstrated that the expression profiles
of mature microRNAs are typical for CML including both
mixed as well as highly purified peripheral blood (PB)-
derived cell populations [51, 52, 53•]. In spite of the differ-
ent biological materials and microarray platforms used in
the studies, the published microRNA expression profiles
clearly distinguished: CML patients from healthy individu-
als [51] and more importantly also found differences be-
tween clinically defined CML phases [53•], and between
patients either responding or not responding to TKI
therapy [54•]. MicroRNA-based expression profiles
may reflect a transformation from CP to AP or BC of
CML [53•]. Despite the different blood cells and methods
used for the microRNA expression profiling, significant
overlap exists, and it may be crucial in understanding
the aberrant CML hematopoiesis as well as the treatment
resistance.
One of the hallmarks of CML is a decreased expression
of miR-150 (in comparison to healthy individuals) in bone
marrow-derived mononuclear cells (MNC) and CD34+ cells
[51] and in MNC [52] and total leukocytes of PB [53•] at
CML diagnosis. A significantly reduced amount of miR-150
was found in MNC [52] and total leukocytes of PB also in
AP and BC [53•]. Moreover, miR-150 was significantly
increased and recovered to the physiological level following
the relatively short therapy with imatinib [52]. This is con-
sistent with the data showing a normal level of miR-150 in
CML patients-responders to imatinib [53•]. Additionally, we
found a uniform profile of the significant decrease of miR-
150 expression in MNC and polymorphonuclear cells
(PMNC) fractionated from peripheral blood of six CML
patients at diagnosis in comparison to the levels in MNC
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and PMNC of healthy individuals. After short treatment
with imatinib (5–7 months from imatinib start), the amount
of miR-150 significantly increased to normal levels in MNC
and PMNC (unpublished data).
In several papers, the amount ofmiR-146awas found to be
significantly decreased at CML diagnosis [51, 52, 53•]. It was
shown that miR-146a expression was normalized after imati-
nib treatment [52, 53•]. A significantly decreased expression
of miR-10a was reported in MNC and CD34+ cells in CML
patients at diagnosis in comparison to healthy controls [51].
Aberrantly decreased levels of miR-10a were confirmed in
MNC of PB at diagnosis [52]. However, after short treatment
with imatinib, the microRNA levels were normalized.
We may find several discrepancies in the microRNA
expression profiles in CML such as the miR-17-92 clus-
ter also known as oncomir-1. The MiR-17-92 is a poly-
cistronic cluster of six microRNAs with their increased
expression levels in CD34+ cells of CML patients at
diagnosis. In contrast, their levels were physiologically
expressed in CD34+ blastic cells [55]. Interestingly, the
expression levels of pri-miR-17-92 were found increased
in CD34+ cells at the CML diagnosis and blast crisis
[55]. We showed that the levels of miR-17-92 were
significantly increased in leukocytes of PB in blast crisis
while levels were normal or slightly increased at diagno-
sis [53]. In addition, Flamant et al. [52] found a decrease
in expression of oncomir-1 in MNC PK 14 days after
starting Imatinib. Recently, in a study with a small cohort
of patients (n=17), it was suggested that the miR-451
expression level found in total leukocytes of PB at diag-
nosis may be associated with the response to IM therapy.
In addition, it was shown that the miR-451 level may
inversely correlate with the BCR-ABL transcript level in
some CML patients [56]. However, expression of miR-
451 appears in this study to be relatively more heteroge-
neous. It was suggested that besides BCR-ABL, other
mediators may be involved in the regulation of miR-
451 expression [56]. Such heterogeneous expression of
miR-451 expression among total leukocytes from CML
patients may be explained by our unpublished data on
the MNC and PMNC fractions from peripheral blood of
six CML patients at diagnosis and after a short imatinib
treatment (5–7 months). We observed that the expression
of miR-451 was significantly reduced at diagnosis in
PMNC, while in MNC, the transcript levels remained
normal. After short treatment with imatinib, accompanied
by a BCR-ABL transcript level reduction, the miR-451
transcript levels were normalized in PMNC and significantly
increased in MNC in comparison to healthy PMNC and
MNC, respectively. Thus, the expression of miR-451 found
in total leukocytes is an average of expression in MNC and
PMNC. In the case of miR-451, the expression profile is rather
dependent on the cell type and its abundance within MNCs.
Bioinformatic Prediction of miRNA Targets in CML
We and others showed that in silico predicted targeted genes
of selected microRNAs may be associated with CML patho-
genesis. The increased levels of 13 miRNAs (miR-19a, miR-
19b, miR-17, miR-20, miR-92a, miR-106a, miR-221, miR-
222, miR-126, miR-146a, miR-181a, miR-181b, let7c, miR-
155) and decreased levels of 4 miRNAs (miR-103, miR-150,
miR-451, miR-144) in PB cells from blast crisis were used to
uncover signaling pathways and their role in CML (Fig. 1)
[53•]. Some of the predicted proteins are involved in mitogen-
activated pathway (MAP) kinase signaling that functionally
interact with BCR-ABL. The miRNAmay also regulate PI3K
(phosphatidylinositol-3-kinase) pathway. The gene encoding
PI3K is the predicted target of miR-181a, miR-221 and miR-
19a (their levels were decreased in CML patients treated with
imatinib) [53•]. Decreased levels of the above mentioned
miRNAs may contribute to the increased levels of PI3K and
thus in the PI3K/AKT/mTOR signaling pathway and it may
potentially regulate resistance development in CML. AKT1 is
a member of the anti-apoptotic pathway of PI3K that is
associated with the BCR-ABL directed transformation and
with the response to the TKI treatment. The PI3K/AKT/
mTOR pathway is activated in imatinib naive cells, but under
imatinib treatment, it may contribute to the resistant pheno-
type [57]. Recent work of Rokah et al. [58] supplemented the
predicted genes in the annotated CML pathways being targets
of miR-155, miR-31 and miR-564 that were found to be
aberrantly expressed in K562 cell lines in comparison to blood
cells of healthy individuals (also see Fig. 1).
MMP16, which drives a membrane transmigration of can-
cer cells, and NFASC were predicted as targets of deregulated
miRNAs in CML: miR-150 and miR-146a. For the other two
deregulated molecules, miR-142-3p and miR-199b-5p, the
following targets were predicted: ACVR2A, ANK3,
ARHGEF12, C18orf25, CCNJ, MAP3K11, MYH9, MYO5A,
RBM47, RHEB, RNF38, and ZNF618 [52]. Genes encoding
proteins that may be important in CML are also ARHGEF12
and MYH9. The ARHGEF12 is known as the LRG encoding
Rho guanin factor gene essential for nucleotide exchange and
was firstly identified as the fusion partner of MLL in acute
myeloid leukemia. The MYH9 encodes the heavy chain of
non-muscle myosin and its upregulation was described in
myeloid cells during differentiation [58]. To conclude this
part, targets of microRNAs may be involved in clinically
relevant tasks in CML, but a detailed understanding of these
targets will require additional studies.
Function of miRNAs Regulated by BCR-ABL
Two important groups of miRNAs may play a significant
role in the CML pathogenesis: (i) miRNAs that are
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downregulated by BCR-ABL and (ii) miRNAs that are
upregulated by BCR-ABL.
Several miRNAs are regulated by BCR-ABL in the Ph+
cell lines:
1) Pri-miR-17-92 transcription is directly regulated by c-
MYC and also by BCR-ABL [55]. The inhibition of c-
MYC using anti-c-MYC specific shRNA together with
imatinib treatment induced the highest reduction in the
amount of pri-miR-17-92 in K562 cells. As a conse-
quence, nearly complete arrest of proliferation was ob-
served following the inhibition of c-MYC expression.
The inhibitory effect on growth of K562 through c-
MYC silencing was partially reverted by the overex-
pression of ectopic construct encoding miR-17-19b.
Altogether, the data support the existence of the BCR-
ABL / c-MYC / miR-17-92 pathway in CML
pathogenesis.
2) MiR-130a is mediated by BCR-ABL in K562 cells [59].
After the BCR-ABL silencing in K562, the levels of miR-
130a and miR-130b significantly decreased, whereas the
expression of their putative target, the growth negative
regulator CCN3, significantly increased. To prove that
CCN3 is the target of miR130a/b, the HL-60 cell line was
transfected individually with both miRNAs showing that
the expression of the tumor suppressor gene CCN3 was
repressed with a different intensity. Finally, overexpres-
sion of miR-130a (but not miR-130b) significantly
inhibited protein expression of its target CCN3.
3) The expression levels of miR-150 significantly in-
creased following the inhibition of the BCR-ABL ac-
tivity by imatinib treatment in the Ph+ cell line
MOLM7 [53•]. The MYB is a proved target gene of
miR-150 and represents a transcription factor for the
proliferation and survival of normal and leukemic
blasts. Experiments on a murine model of BC CML
showed that c-MYB is required for BCR-ABL driven
leukemogenesis [60]. Thus, the reduction of miR-150
might contribute to the up-regulation of c-MYB.
Moreover, an observed significant inverse correlation
of miR-150 and MYB and with BCR-ABL expressions
and a significant positive correlation of MYB with the
BCR-ABL transcript levels support the above men-
tioned conclusions [53•]. The network between BCR-
ABL, miR-150 and MYB needs to be further clarified
and tested for some expected clinical benefit.
4) The differentiation arrest in the myeloid blastic phase of
CML depends on the BCR-ABL-MAPK induced activ-
ity of hnRNP E2. The hnRNP E2 is a poly(rC)-binding
protein that controls the translation of specific mRNAs.
The induced activity of hnRNP E2 in CML blast crisis
silences miR-328, thus the pro-apoptotic effect is
arrested through the PIM1 overexpression. PIM1 is an
oncogene encoding a serine/threonine kinase, inducing
cell proliferation and survival [61]. In association with
the described BCR-ABL-MAPK-hnRNP E2- miR-328
pathway, the authors rediscovered a novel function for
microRNA – a decoy activity. The hnRNP E2 sup-
presses the translation and synthesis of the transcription
factor CCAAT/enhancer binding protein (C/EBP), al-
pha (CEBPA, that is essential for myeloid differentia-
tion) through the C-rich element in 5’UTR mRNA of
CEBPA. The MiR-328 interacts outside its “seed se-
quence” with hnRNP E2 with a higher affinity than
between hnRNP E2 and mRNA CEBPA. The interaction
between miR-328 and hnRNP E2 enables the translation
of CEBPA, thus a myeloid differentiation is induced.
Moreover, there is a feedback loop as C/EBPalpha indu-
ces the transcription of pri-miR-328 that might be pre-
vented by hnRNP E2 through the BCR-ABL induced
MAPK hnRNP E2 signaling pathway [61].
MicroRNAs may Directly Target BCR-ABL
The identification of miRNAs that directly target the expres-
sion of BCR-ABL may play a role in the microRNA-based
therapy in CML. A recent study showed that normal ABL,
and also BCR-ABL, are targets of miR-203 [62]. The pre-
dicted duplexes, formed between the miR-203 “seed se-
quence” and 3 ’UTR of ABL , showed complete
complementarity. The 3’UTR region of ABL is present in
the BCR-ABL fusion gene. It was observed that the upstream
region of the gene encoding miR-203 was hypermethylated
in Ph+ leukemias, resulting in the absence of miR-203.
After the reintroduction of miR-203 into the CML cell lines,
K562 and KCL-22, expression of miR-203 was restored.
Additionally, it was accompanied by an ABL and BCR-
ABL decrease and dramatic reduction in the cell prolifera-
tion. It was shown that epigenetic inactivation through pro-
moter region methylation of miR-203 might allow
expression of ABL and BCR-ABL to escape the regulatory
control. Epigenetic regulation of miR-203 expression repre-
sents an example of aberrant hypermethylation of the
Fig. 1 Scheme of CML hematopoietic stem cell signaling pathways in
which predicted targets of microRNAs associated with CML are in-
volved. A. microRNAs identified by Machova Polakova et al. [53•]:
miR-103, miR-150 and miR-144 were found to be decreased in pe-
ripheral blood cells of blast crisis, while other illustrated micoRNAs
were increased; B. microRNAs identified by Rokah et al. [58]: all four
illustrated microRNAs were found to be decreased in the K562 cell
line. MAPK pathway is shown in blue, Transforming growth factor
beta signaling pathway in purple and cell cycle with p53 pathway in
green. Note: the scheme is modified according to the hsa05220 of the
KEGG database (Kanehisa M, Goto S, Furumichi M, et al.: KEGG for
representation and analysis of molecular networks involving diseases
and drugs. Nucleic Acids Res. 2010, 38:D355-D360.)
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promoter region of genes encoding microRNAs leading to
an inappropriate increase of oncogene levels.
Conclusion
Significant progress in CML treatment has been achieved
since the introduction of first and 2nd line tyrosine kinase
inhibitors. Despite the high efficiency of the TKI therapy,
some patients developed resistance due to mutations in the
BCR-ABL kinase domain, resulting in therapy failure.
Other mechanisms of resistance are not fully understood.
Abnormal epigenetic regulation of the expression of impor-
tant genes may play a critical role in the pathogenesis of
CML and its resistance to therapy. Since epigenetic changes
have the potential to be modulated, new drugs targeting
different epigenetic mechanisms are strongly considered
for the therapy of CML especially those that developed
resistance to imatinib including demethylated agents and
HDAC inhibitors. MicroRNAs are also potentially very
important in the pathogenesis of CML. In the future,
microRNA-based therapy is planned to be one of the
approaches in CML management. This requires that we
improve the chemical design of microRNA antisense oligo-
nucleotides and microRNA mimics and we must to develop
efficient delivery methods for microRNAs. Lastly, recent
progress in biotechnology and bioinformatics provides nov-
el promising tools (such as next generation sequencing) for
de novo epigenetic factors characterization and deeper un-
derstanding of the epigenetic mechanisms to be successfully
utilized for personalized CML therapy in the future.
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